Active Filter(s):
Details:
The study achieved its primary endpoint that demonstrated a significant correlation between DetermaIO and two-year overall survival in atezolizumab treated metastatic bladder cancer.
Lead Product(s): Atezolizumab,Bevacizumab,Fluorouracil
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022